NCT02551172

Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD

An Efficacy and Safety Study of HCP1105 Capsule in Combined Hyperlipidemic Patients With High Risk for Coronary Heart Disease (CHD): A Randomized,Double-blind, Multicenter, Phase 3 Study

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 270 (estimated)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

To investigate the efficacy and safety after administration of HCP1105 in hyperlipidemic patients with high risk for CHD.

Detailed description

An efficacy and safety study of HCP1105 Capsule in combined hyperlipidemic patients with high risk for Coronary Heart Disease(CHD): A randomized,double-blind, multicenter, phase 3 study.

Conditions

• Hyperlipidemias

Interventions

Type	Name	Description
DRUG	HCP1105	Rosuvastatin + Omega-3-acids ethyl esters
DRUG	HGP0816	Rosuvastatin
DRUG	Placebo of HCP1105	Soybean Oil
DRUG	Placebo of HGP0816	Exclusion of Rosuvastatin in HGP0816

Timeline

• Start date: 2014-10-01
• Primary completion: 2016-01-01
• Completion: 2016-02-01
• First posted: 2015-09-16
• Last updated: 2015-09-16

Locations

1 site across 1 country: South Korea